vandetanib plus docetaxel vs placebo plus docetaxel | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
vandetanib vs | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Vandetanib vs gefitinib | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Vandetanib vs placebo | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
vandetanib maintenance vs | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Vandetanib plus pemetrexed vs | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Vandetanib versus gefitinib vs | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |